know before you go

Everything you need to know about SXSW’s anticipated in-person return to Austin

Make your SXSW plan — SXSW starts today. SXSW/Instagram

SXSW starts this week, and it’s the first in-person event since 2019, which had more than 400,000 people attend.

The Austin Convention Center will play host to SXSW EDU through Thursday, March 10; SXSW Film Fest runs from Friday, March 11-Saturday, March 19; SXSW Music Fest runs from Monday, March 14-Sunday, March 20, Interactive runs from Friday, March 11-Saturday, March 19, and Flatstock 77 runs from Thursday, March 17- Saturday, March 19. At the Palmer Events Center, the SXSW Wellness Expo will be held from Saturday, March 12-Sunday, March 13.

Click here for your guide to connecting with Houston innovators this year at SXSW.

If you’re one of the many people attending, here are some things you should know before you go.

First things first: COVID-19 protocols. Austin is now in Stage 2 of its COVID-19 risk-based guidelines, and SXSW has made the decision to keep its existing guidelines in place. That means anyone who is attending needs to provide proof of vaccination against COVID-19 or a negative COVID-19 test in order to pick up credentials.

Speaking of credentials, they can only be issued to, picked up by, and used by the participant named in the registration. All badge types can be picked up at Exhibit Hall 1 of the Austin Convention Center through March 19. For a list of the SXSW credential pickup dates and times, click here. Don’t forget to bring a government-issued photo ID and verification of vaccination or recent negative COVID-19 test.

As for getting around, you can catch a free ride on one of the circulating festival shuttles. You can also use pedicabs or public transit, or you can park close by and do some walking. Most of the venues are walkable and within a few minutes of the Austin Convention Center. For a look at road closures and commuting options, click here.

One way to help organize your time is by downloading the SXSW GO app. From the app, you can link your badge, RSVP for events, build your schedule, and sign up for notifications so you don’t miss those things you really want to see.

SXSW is a huge festival featuring events for many different genres, including music, film, television, gaming, and more. It will be difficult to attend everything you want.

Here’s some advice from Jim Kolmar, consulting film programmer for SXSW, and long-time attendee.

“I always tell people pick out three things you really want to do and make sure you do those,” he says. “Everything else, just have a plan, but leave it open to serendipity because your plan is going to fall apart at some point. There’s just no way to do everything exactly the way you want to. And I think that’s the best way to experience it, too. Just be in the moment.”

For those who don’t want to spend money but still want a SXSW experience, you can subscribe to free events here.

---

Continue reading this story and watch the video on KVUE.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted